Wang Yongyu, Hu Jiang, Jiao Jiao, Liu Zhongning, Zhou Zhou, Zhao Chao, Chang Lung-Ji, Chen Y Eugene, Ma Peter X, Yang Bo
Department of Cardiac Surgery, Cardiovascular Center, The University of Michigan, Ann Arbor, MI 48109, USA.
Department of Biologic and Materials Sciences, The University of Michigan, Ann Arbor, MI 48109, USA.
Biomaterials. 2014 Oct;35(32):8960-9. doi: 10.1016/j.biomaterials.2014.07.011. Epub 2014 Jul 29.
Tissue-engineered blood vessels (TEBVs) are promising in the replacement of diseased vascular tissues. However, it remains a great challenge to obtain a sufficient number of functional smooth muscle cells (SMCs) in a clinical setting to construct patient-specific TEBVs. In addition, it is critical to develop a scaffold to accommodate these cells and retain their functional phenotype for the regeneration of TEBVs. In this study, human induced pluripotent stem cells (iPSCs) were established from primary human aortic fibroblasts, and characterized with the pluripotency markers expression and cells' capabilities to differentiate into all three germ layer cells. A highly efficient method was then developed to induce these human iPSCs into proliferative SMCs. After multiple times of expansion, the expanded SMCs retained the potential to be induced into the functional contractile phenotype of mature SMCs, which was characterized by the contractile response to carbachol treatment, up-regulation of specific collagen genes under transforming growth factor β1 treatment, and up-regulation of specific matrix metalloproteinase genes under cytokine stimulation. We also developed an advanced macroporous and nanofibrous (NF) poly(l-lactic acid) (PLLA) scaffold with suitable pore size and interpore connectivity to seed these human iPSC-derived SMCs and maintain their differentiated phenotype. Subcutaneous implantation of the SMC-scaffold construct in nude mice demonstrated vascular tissue formation, with robust collagenous matrix deposition inside the scaffold and the maintenance of differentiated SMC phenotype. Taken together, this study established an exciting approach towards the construction of patient-specific TEBVs. We established patient-specific human iPSCs, derived proliferative SMCs for expansion, turned on their mature contractile SMC phenotype, and developed an advanced scaffold for these cells to regenerate vascular tissue in vivo.
组织工程血管(TEBVs)在替代病变血管组织方面具有广阔前景。然而,在临床环境中获得足够数量的功能性平滑肌细胞(SMCs)以构建患者特异性TEBVs仍然是一个巨大的挑战。此外,开发一种支架来容纳这些细胞并保持其功能表型以实现TEBVs的再生至关重要。在本研究中,从原代人主动脉成纤维细胞建立了人诱导多能干细胞(iPSCs),并通过多能性标志物表达以及细胞分化为所有三个胚层细胞的能力进行了表征。然后开发了一种高效方法将这些人iPSCs诱导为增殖性SMC。经过多次扩增后,扩增的SMC保留了被诱导为成熟SMC功能性收缩表型的潜力,其特征在于对卡巴胆碱治疗的收缩反应、在转化生长因子β1治疗下特定胶原基因的上调以及在细胞因子刺激下特定基质金属蛋白酶基因的上调。我们还开发了一种具有合适孔径和孔间连通性的先进大孔和纳米纤维(NF)聚(L-乳酸)(PLLA)支架,用于接种这些人iPSC衍生的SMC并维持其分化表型。将SMC-支架构建体皮下植入裸鼠体内显示出血管组织形成,支架内有大量胶原基质沉积且维持了分化的SMC表型。综上所述,本研究建立了一种令人兴奋的构建患者特异性TEBVs的方法。我们建立了患者特异性人iPSCs,获得了用于扩增的增殖性SMC,开启了其成熟的收缩性SMC表型,并开发了一种先进的支架以使这些细胞在体内再生血管组织。